STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease
Business Wire - Mon Sep 28, 11:07AM CDT
STENTYS (Paris:STNT)(FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that the Company's Drug-Eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries, making STENTYS' product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.
STENTYS Reports First Half 2015 Financial Results
Business Wire - Thu Sep 17, 11:57AM CDT
--Gross margin up 1,400 basis points to 53%
STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015
Business Wire - Wed Jul 08, 11:16AM CDT
STENTYS (Paris:STNT) (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces its revenues and cash position at June 30, 2015.
STENTYS Reports First Quarter 2015 Revenues Rose 28%
Business Wire - Thu Apr 16, 11:14AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announces revenues for the first quarter of 2015.
STENTYS 2014 Annual Results
Business Wire - Tue Mar 31, 12:22PM CDT
--Solid cash position of EUR18.6 million allowing the commercial launch of the new product portfolio
STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
Business Wire - Wed Jan 28, 11:25AM CST
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing the world's first and only Self-Apposing(R) coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them.
STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent
Business Wire - Mon Nov 03, 10:54AM CST
Regulatory News :
STENTYS' Sirolimus-Eluting Stent Receives CE Marking
Business Wire - Mon Oct 27, 12:50PM CDT
Regulatory News:
STENTYS Revenues for the First 9 Months of 2014 up 16.9%
Business Wire - Thu Oct 23, 10:45AM CDT
STENTYS (Paris:STNT) (FR0010949404 -- STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing(R) stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.
STENTYS Wins Large Regional Tender in Middle East
Business Wire - Mon Oct 20, 12:17PM CDT
Regulatory News:
STENTYS Stent Continues to Show Low Mortality Two Years after Treatment of a Heart Attack
Business Wire - Tue Sep 16, 11:12AM CDT
Regulatory News :